Nebacumab: Difference between revisions
Content deleted Content added
Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Entranced98 (talk | contribs) Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound" |
||
| (13 intermediate revisions by 11 users not shown) | |||
| Line 1: | Line 1: | ||
| ⚫ | |||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| verifiedrevid = |
| verifiedrevid = 458283142 |
||
| image = |
| image = |
||
<!-- Monoclonal antibody data --> |
|||
| ⚫ | |||
| type = mab |
| type = mab |
||
| mab_type = mab |
| mab_type = mab |
||
| source = u |
| source = u |
||
| target = endotoxin |
| target = endotoxin |
||
| ⚫ | |||
| ⚫ | |||
| tradename = |
| tradename = |
||
| Drugs.com = {{drugs.com|international|nebacumab}} |
| Drugs.com = {{drugs.com|international|nebacumab}} |
||
| Line 22: | Line 21: | ||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
| ⚫ | |||
| ⚫ | |||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
| Line 29: | Line 27: | ||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| ⚫ | |||
| UNII = 908FWN27WK |
|||
| ATC_prefix = J06 |
| ATC_prefix = J06 |
||
| ATC_suffix = BC01 |
| ATC_suffix = BC01 |
||
| Line 41: | Line 40: | ||
| KEGG = D05126 |
| KEGG = D05126 |
||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = |
| ChemSpiderID = none |
||
| ⚫ | |||
| ⚫ | |||
| chemical_formula = |
| chemical_formula = |
||
| molecular_weight = |
| molecular_weight = |
||
}} |
}} |
||
'''Nebacumab''' is a [[human]] [[monoclonal antibody]] developed for the treatment of [[sepsis]].<ref>{{ |
'''Nebacumab''' is a [[human]] [[monoclonal antibody]] developed for the treatment of [[sepsis]].<ref>{{cite journal | vauthors = Derkx B, Wittes J, McCloskey R | title = Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group | journal = Clinical Infectious Diseases | volume = 28 | issue = 4 | pages = 770–7 | date = April 1999 | pmid = 10825037 | doi = 10.1086/515184 | doi-access = free }}</ref> It has been withdrawn in 1993 because it failed to reduce mortality in [[clinical trial]]s.<ref>[https://web.archive.org/web/20091107133217/http://apps.who.int/medicinedocs/en/d/Js4902e/4.1.262.html#Js4902e.4.1.262 WHO: Consolidated List of Products]</ref> |
||
==References== |
== References == |
||
{{reflist}} |
{{reflist}} |
||
| Line 57: | Line 54: | ||
{{Immune sera and immunoglobulins}} |
{{Immune sera and immunoglobulins}} |
||
| ⚫ | |||
[[Category:Withdrawn drugs]] |
|||
[[Category:Abandoned drugs]] |
|||
{{antiinfective-drug-stub}} |
{{antiinfective-drug-stub}} |
||
{{monoclonal-antibody-stub}} |
{{monoclonal-antibody-stub}} |
||
| ⚫ | |||